A client with a dinoprostone vaginal insert develops uterine tachysystole with recurrent late fetal-heart-rate decelerations. Which action should the nurse take first?
1Begin oxytocin at the prescribed rate while leaving the insert in place, then reassess the tracing after 30 minutes.
2Keep the insert in place until the next cervical examination while providing a lateral position and oxygen.
3Remove the insert now and begin the authorized intrauterine-resuscitation measures while reassessing the fetal response.✓ Correct answer
4Advance the insert farther into the posterior fornix, reduce stimulation, and continue continuous fetal monitoring.
Explanation
The removable dinoprostone insert should be removed for tachysystole, fetal distress, or before oxytocin. Immediate removal ends further drug delivery while the fetal response is addressed.
Quick answer For CERVIDIL, tachysystole plus late decelerations means remove the insert now.
Why this is correct Leaving the controlled-release insert in place continues prostaglandin exposure during fetal compromise.
Easy analogy or mental picture Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.
Memory hook Drug, urgent cue, protective action, and reassessment endpoint.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.
References
1DailyMed: CERVIDIL (dinoprostone insert)Removal for tachysystole or fetal distress and before oxytocin
Medication-safety reviewVerify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.